Following the Philips recall, significant changes happened in the competitive landscape of the homecare respiratory market.

ResMed became the dominant market leader holding ~50% of the global homecare respiratory market. Significant market share gain in last 3 years was due to spillover of Philips shares, as ResMed was perceived as the closest technology substitute. With such a high share, ResMed will be defending its market position in years to come.

Löwenstein and Breas are strong on their home turf – the European market. However, there exists a lot to gain on the global market by going after ResMed’s high market shares. It is expected to have both companies strengthen their market presence, especially focusing on the regions they are not present.

Chinese companies are strongly penetrating the global market, especially focusing on Europe and the USA. It is just a matter of time before these companies manage to break through and become credible competitors in developed economies’ markets. They are penetrating mainly via xPAP technologies.